Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Research in Cardiology
Metadata
Title
„Totengespräche“Ein postmortales, kardiologisches Symposium
Ein postmortales, kardiologisches Symposium
Author
Paul Heintzen
Publication date
01-12-2000
Publisher
Steinkopff-Verlag
Published in
Clinical Research in Cardiology / Issue 12/2000
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s003920070143

Other articles of this Issue 12/2000

Clinical Research in Cardiology 12/2000 Go to the issue

INTERVENTIONELLE VERFAHREN/CHIRURGIE

Das atriale natriuretische Peptid als Indikator einer milden postoperativen kardialen Dysfunktion nach unkomplizierter Bypasschirurgie

RHYTHMUSSTÖRUNGEN

Herzrhythmusstörungen bei gezielt Connexin-defizienten Mäusen: Bedeutung für die Rhythmologie

ANTITHROMBOTISCHE THERAPIE

Coexistence of factor V Leiden and primary antiphospholipid syndrome: a patient with recurrent myocardial infarctions and thrombocytopenia

ANTITHROMBOTISCHE THERAPIE

Intravenöse Langzeit-Thrombolyse eines verschlossenen aortocoronaren Venenbypassgefäßes

OriginalPaper

Stichwortregister zu Band 89 (2000)

INTERVENTIONELLE VERFAHREN/CHIRURGIE

Interventioneller Verschluss von Vorhofseptumdefekten mit einem Duchmesser größer als 20mm

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits